Article
Sarepta says FDA may limit gene therapy nod to smaller population, shares fall
Rating:
0.0
Views:
56
Likes:
1
Library:
1
Sarepta Therapeutics Inc said the U.S. drug regulator could initially approve its gene therapy for a muscle wasting disorder for a smaller patient group after the agency deferred an accelerated approval decision, sending its shares down 7%.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value